Your shopping cart is currently empty

Befiradol hydrochloride (NLX-112 hydrochloride) is a selective 5-hydroxytryptamine 1A (5-HT1A) receptor agonist with anxiolytic properties and inhibits mutant ATXN3 aggregation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $106 | - | In Stock | |
| 5 mg | $265 | - | In Stock | |
| 10 mg | $387 | - | In Stock | |
| 25 mg | $623 | - | In Stock | |
| 50 mg | $861 | - | In Stock | |
| 100 mg | $1,150 | - | In Stock | |
| 200 mg | $1,550 | - | In Stock |
| Description | Befiradol hydrochloride (NLX-112 hydrochloride) is a selective 5-hydroxytryptamine 1A (5-HT1A) receptor agonist with anxiolytic properties and inhibits mutant ATXN3 aggregation. |
| In vivo | Befiradol hydrochloride (F13640 hydrochloride; NLX-112 hydrochloride) decreases the activity of dorsal raphe serotonergic neurons when administered intravenously at doses ranging from 0.2 to 18.2 μg/kg, with an effective dose (ED50) of 0.69 μg/kg, i.v. At the same dosage range, it enhances the firing rate of 80% of the medial prefrontal cortex (mPFC) pyramidal neurons, with an ED50 of 0.62 μg/kg, i.v.[1] Befiradol hydrochloride (0.04-0.63 mg/kg; i.p.) dose-dependently decreases extracellular 5-HT in the hippocampus and mPFC.[1] Befiradol hydrochloride (0.01-2.5 mg/kg; i.p.) dose-dependently increases extracellular DA in mPFC, an effect dependent on the activation of postsynaptic 5-HT1A receptors in mPFC. Local perfusion of Befiradol hydrochloride in mPFC (1-1000 μM) also increases extracellular DA in a concentration-dependent manner.[1] |
| Synonyms | NLX-112 hydrochloride, F 13640 hydrochloride |
| Molecular Weight | 430.32 |
| Formula | C20H23Cl2F2N3O |
| Cas No. | 2436760-81-3 |
| Smiles | Cl.O=C(C1=CC=C(F)C(Cl)=C1)N2CCC(F)(CNCC3=NC=C(C=C3)C)CC2 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 43.03 mg/mL (100 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.65 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.